Tumor-Induced Osteomalacia Market Size, Share, Trends, Industry Analysis Report: By Treatment Type, End Users, and Region

Description

List of Tables

The tumor-induced osteomalacia market size is expected to reach USD 153.00 million by 2034, according to a new study by Polaris Market Research. The report "Tumor-Induced Osteomalacia Market Size, Share, Trends, Industry Analysis Report: By Treatment Type (Drugs & Supplements and Surgery), End Users (Hospitals, Ambulatory Surgery Centers, Speciality Clinics, and Others), and Region (North America, Europe, Asia Pacific, Latin America and the Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The tumor-induced osteomalacia (TIO) market is driven by increasing awareness of rare bone disorders, advancements in diagnostic techniques, and the rising prevalence of TIO, which is linked to various tumours causing phosphate wasting and bone mineralisation issues. The market benefits from opportunities related to the development of targeted therapies and novel treatments, as well as the growing investment in research for effective management of the condition.

Expected market trends include a focus on personalised medicine and the utilisation of genetic and molecular diagnostics to identify and treat TIO more accurately. Overall, the market is experiencing growth due to enhanced understanding of the disease mechanisms, improving patient outcomes, and the expanding pipeline of therapeutic options.

Tumor-Induced Osteomalacia Market Report Highlights

By treatment type analysis, the drugs and supplements segment dominates the tumor-induced osteomalacia market due to their crucial role in managing the condition through phosphate replacement and targeted therapies. However, surgery is gaining traction as a significant growth area with advancements in surgical techniques and increased focus on tumour resection.

By end users analysis, the hospitals lead the market as the primary setting for TIO diagnosis and treatment, offering comprehensive care and specialised equipment. Ambulatory surgery centers are experiencing rapid growth, driven by advancements in minimally invasive procedures and increasing patient preference for outpatient care.

North America is the dominant region in the TIO market, attributed to advanced healthcare infrastructure and significant research investments. Asia Pacific is the highest-growing region, driven by improving healthcare facilities, increasing awareness, and a growing patient population.

Key players actively involved in the tumor-induced osteomalacia (TIO) market include Ultragenyx Pharmaceutical Inc., Kyowa Kirin Co., Ltd., Eli Lilly and Company, Amgen Inc., Novartis AG, Sanofi S.A., Pfizer Inc., AbbVie Inc., and Horizon Therapeutics.

Polaris market research has segmented the tumor-induced osteomalacia market report based on treatment type, end users, and region:

By Treatment Type Outlook (Revenue - USD Million, 2020-2034)

Drugs & Supplements
Surgery

By End Users Outlook (Revenue - USD Million, 2020-2034)

Hospitals
Ambulatory Surgery Centers
Speciality Clinics
Others

By Regional Outlook (Revenue - USD Million, 2020-2034)

North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of the Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America

Product Code: PM5232

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. Global Tumor-Induced Osteomalacia Market Insights

4.1. Tumor-Induced Osteomalacia Market - Market Snapshot
4.2. Tumor-Induced Osteomalacia Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Increasing Focus on Targeted Therapies
  - 4.2.1.2. Rising Awareness and Diagnosis of Rare Diseases
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. High Treatment Costs
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Tumor-Induced Osteomalacia Market Application Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Tumor-Induced Osteomalacia Market, by Treatment Type

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
5.3. Drugs & Supplements
- 5.3.1. Global Tumor-Induced Osteomalacia Market, by Drugs & Supplements, by Region, 2020-2034 (USD Million)
5.4. Surgery
- 5.4.1. Global Tumor-Induced Osteomalacia Market, Surgery, by Region, 2020-2034 (USD Million)

6. Global Tumor-Induced Osteomalacia Market, by End User

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
6.3. Hospitals
- 6.3.1. Global Tumor-Induced Osteomalacia Market, by Hospitals, by Region, 2020-2034 (USD Million)
6.4. Ambulatory Surgery Centers
- 6.4.1. Global Tumor-Induced Osteomalacia Market, by Ambulatory Surgery Centers, by Region, 2020-2034 (USD Million)
6.5. Speciality Clinics
- 6.5.1. Global Tumor-Induced Osteomalacia Market, by Speciality Clinics, by Region, 2020-2034 (USD Million)
6.6. Others
- 6.6.1. Global Tumor-Induced Osteomalacia Market, by Others, by Region, 2020-2034 (USD Million)

7. Global Tumor-Induced Osteomalacia Market, by Geography

7.1. Key Findings
7.2. Introduction
- 7.2.1. Tumor-Induced Osteomalacia Market Assessment, By Geography, 2020-2034 (USD Million)
7.3. Tumor-Induced Osteomalacia Market - North America
- 7.3.1. North America: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.3.2. North America: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.3.3. Tumor-Induced Osteomalacia Market - U.S.
  - 7.3.3.1. U.S.: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  - 7.3.3.2. U.S.: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.3.4. Tumor-Induced Osteomalacia Market - Canada
  - 7.3.4.1. Canada: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  - 7.3.4.2. Canada: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
7.4. Tumor-Induced Osteomalacia Market - Europe
- 7.4.1. Europe: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.4.2. Europe: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.4.3. Tumor-Induced Osteomalacia Market - UK
  - 7.4.3.1. UK: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  - 7.4.3.2. UK: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.4.4. Tumor-Induced Osteomalacia Market - France
  - 7.4.4.1. France: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  - 7.4.4.2. France: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.4.5. Tumor-Induced Osteomalacia Market - Germany
  - 7.4.5.1. Germany: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  - 7.4.5.2. Germany: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.4.6. Tumor-Induced Osteomalacia Market - Italy
  - 7.4.6.1. Italy: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  - 7.4.6.2. Italy: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.4.7. Tumor-Induced Osteomalacia Market - Spain
  - 7.4.7.1. Spain: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  - 7.4.7.2. Spain: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.4.8. Tumor-Induced Osteomalacia Market - Netherlands
  - 7.4.8.1. Netherlands: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  - 7.4.8.2. Netherlands: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.4.9. Tumor-Induced Osteomalacia Market - Russia
  - 7.4.9.1. Russia: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  - 7.4.9.2. Russia: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.4.10. Tumor-Induced Osteomalacia Market - Rest of Europe
  - 7.4.10.1. Rest of Europe: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  - 7.4.10.2. Rest of Europe: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
7.5. Tumor-Induced Osteomalacia Market - Asia Pacific
- 7.5.1. Asia Pacific: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.5.2. Asia Pacific: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.5.3. Tumor-Induced Osteomalacia Market - China
  - 7.5.3.1. China: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  - 7.5.3.2. China: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.5.4. Tumor-Induced Osteomalacia Market - India
  - 7.5.4.1. India: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  - 7.5.4.2. India: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.5.5. Tumor-Induced Osteomalacia Market - Malaysia
  - 7.5.5.1. Malaysia: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  - 7.5.5.2. Malaysia: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.5.6. Tumor-Induced Osteomalacia Market - Japan
  - 7.5.6.1. Japan: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  - 7.5.6.2. Japan: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.5.7. Tumor-Induced Osteomalacia Market - Indonesia
  - 7.5.7.1. Indonesia: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  - 7.5.7.2. Indonesia: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.5.8. Tumor-Induced Osteomalacia Market - South Korea
  - 7.5.8.1. South Korea: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  - 7.5.8.2. South Korea: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.5.9. Tumor-Induced Osteomalacia Market - Australia
  - 7.5.9.1. Australia: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  - 7.5.9.2. Australia: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.5.10. Tumor-Induced Osteomalacia Market - Rest of Asia Pacific
  - 7.5.10.1. Rest of Asia Pacific: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  - 7.5.10.2. Rest of Asia Pacific: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
7.6. Tumor-Induced Osteomalacia Market - Middle East & Africa
- 7.6.1. Middle East & Africa: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.6.2. Middle East & Africa: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.6.3. Tumor-Induced Osteomalacia Market - Saudi Arabia
  - 7.6.3.1. Saudi Arabia: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  - 7.6.3.2. Saudi Arabia: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.6.4. Tumor-Induced Osteomalacia Market - UAE
  - 7.6.4.1. UAE: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  - 7.6.4.2. UAE: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.6.5. Tumor-Induced Osteomalacia Market - Israel
  - 7.6.5.1. Israel: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  - 7.6.5.2. Israel: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.6.6. Tumor-Induced Osteomalacia Market - South Africa
  - 7.6.6.1. South Africa: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  - 7.6.6.2. South Africa: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.6.7. Tumor-Induced Osteomalacia Market - Rest of Middle East & Africa
  - 7.6.7.1. Rest of Middle East & Africa: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  - 7.6.7.2. Rest of Middle East & Africa: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
7.7. Tumor-Induced Osteomalacia Market - Latin America
- 7.7.1. Latin America: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.7.2. Latin America: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.7.3. Tumor-Induced Osteomalacia Market - Mexico
  - 7.7.3.1. Mexico: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  - 7.7.3.2. Mexico: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.7.4. Tumor-Induced Osteomalacia Market - Brazil
  - 7.7.4.1. Brazil: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  - 7.7.4.2. Brazil: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.7.5. Tumor-Induced Osteomalacia Market - Argentina
  - 7.7.5.1. Argentina: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  - 7.7.5.2. Argentina: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.7.6. Tumor-Induced Osteomalacia Market - Rest of Latin America
  - 7.7.6.1. Rest of Latin America: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
  - 7.7.6.2. Rest of Latin America: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)

8. Competitive Landscape

8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

9.1. Ultragenyx Pharmaceutical Inc.
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
9.2. Kyowa Kirin Co., Ltd.
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
9.3. Eli Lilly and Company
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
9.4. Amgen Inc.
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
9.5. Novartis AG
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
9.6. Sanofi S.A.
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
9.7. Pfizer Inc.
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
9.8. AbbVie Inc.
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
9.9. Horizon Therapeutics
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development